Barclays PLC Purchases 172,745 Shares of Allogene Therapeutics, Inc. (NASDAQ:ALLO)

Barclays PLC grew its position in Allogene Therapeutics, Inc. (NASDAQ:ALLOFree Report) by 101.5% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 342,973 shares of the company’s stock after buying an additional 172,745 shares during the period. Barclays PLC’s holdings in Allogene Therapeutics were worth $959,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently modified their holdings of the company. Perceptive Advisors LLC purchased a new stake in Allogene Therapeutics during the second quarter valued at approximately $6,349,000. Lynx1 Capital Management LP acquired a new position in shares of Allogene Therapeutics during the second quarter worth $5,192,000. Renaissance Technologies LLC lifted its holdings in shares of Allogene Therapeutics by 340.4% during the 2nd quarter. Renaissance Technologies LLC now owns 1,747,955 shares of the company’s stock valued at $4,073,000 after purchasing an additional 1,351,055 shares during the last quarter. Zacks Investment Management acquired a new stake in shares of Allogene Therapeutics in the 3rd quarter worth $1,446,000. Finally, Dimensional Fund Advisors LP grew its stake in Allogene Therapeutics by 24.8% during the 2nd quarter. Dimensional Fund Advisors LP now owns 2,550,640 shares of the company’s stock worth $5,944,000 after buying an additional 507,021 shares during the last quarter. Hedge funds and other institutional investors own 83.63% of the company’s stock.

Allogene Therapeutics Price Performance

NASDAQ ALLO opened at $1.92 on Wednesday. The company has a fifty day moving average of $2.30 and a 200 day moving average of $2.53. The company has a market capitalization of $402.57 million, a PE ratio of -1.23 and a beta of 0.86. Allogene Therapeutics, Inc. has a 1 year low of $1.78 and a 1 year high of $5.78.

Analyst Upgrades and Downgrades

A number of research firms have commented on ALLO. HC Wainwright reiterated a “buy” rating and issued a $9.00 price target on shares of Allogene Therapeutics in a research note on Friday, November 8th. Piper Sandler lowered their target price on shares of Allogene Therapeutics from $11.00 to $9.00 and set an “overweight” rating for the company in a research note on Thursday, November 14th. Finally, William Blair restated an “outperform” rating on shares of Allogene Therapeutics in a research note on Thursday, November 14th. One research analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $9.73.

Get Our Latest Report on Allogene Therapeutics

About Allogene Therapeutics

(Free Report)

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).

Featured Articles

Want to see what other hedge funds are holding ALLO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allogene Therapeutics, Inc. (NASDAQ:ALLOFree Report).

Institutional Ownership by Quarter for Allogene Therapeutics (NASDAQ:ALLO)

Receive News & Ratings for Allogene Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allogene Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.